+ T cells synergized with rapamycin to induce long-term graft survival in fully MHC-mismatched murine heart transplantation, which was associated with decreased IFN-c, IL-17 and increased IL-10, TGF-b, Foxp3 and Nrp1 expression in the grafts. Importantly, our data indicated that CD4
+

CD25
2 Nrp1 + T cells in the setting of the transplant immune response. Through MLR assays, we found that CD4 +
2 Nrp1 + T cells suppressed the proliferation of naive CD4 +
T cells activated by allogeneic antigen-stimulation. Adoptive transfer of CD4
+ CD25 2 Nrp1 + T cells synergized with rapamycin to induce long-term graft survival in fully MHC-mismatched murine heart transplantation, which was associated with decreased IFN-c, IL-17 and increased IL-10, TGF-b, Foxp3 and Nrp1 expression in the grafts. Importantly, our data indicated that CD4
+ CD25 2 Nrp1 + T cell transfer augments the accumulation of Tregs in the recipient, and creates conditions that favored induction of hyporesponsiveness of the T effector cells. In conclusion, this translational study indicates the possible therapeutic potential of CD4 +
CD25
2 Nrp1 + T cells in preventing allorejection. CD4 + Nrp1 + T cells might therefore be used in bulk as a population of immunosuppressive cells with more beneficial properties concerning ex vivo isolation as compared to Foxp3 + Tregs.
Introduction
Induction and maintenance of donor-specific transplant tolerance is the Holy Grail of organ transplantation that would obviate allorejection and patients' dependency on life-long immunosuppressive treatment [1] . Suppressive cell based therapies have proved to be efficient in promoting tolerance in experimental models [2, 3] . Among them, CD4 + CD25
+
Foxp3
+ regulatory T (Treg) cells have drawn considerable attention. Adoptively transferred naturally occurring Tregs have been demonstrated to promote MHC-incompatible organ graft survival in immunologically impaired host rodents, including irradiated [4] , Rag2-deficient [5] , and T cell-depleted animals [6] . Furthermore, it has been established that the combined treatment of Tregs and a short course of rapamycin is capable to prolong cardiac allograft survival in immunocompetent recipients [7] . However, the population of immunosuppressive T cell is phenotypically and functionally heterogeneous. Increasing evidence indicated that non-Treg immunosuppressive T cells could also be found among CD4 + CD25 [10] .
Neuropilin-1 (Nrp1), a multifunctional type 1 transmembrane protein involved in axonal guidance as a receptor for semaphorin-3A [11] and in angiogenesis through interactions with vascular endothelial growth factor [12] , has been reported as a potent surface marker for murine CD4 + CD25 + Treg cells [13] . Consistently, we observed in previous study that freshly isolated CD3 + Nrp1 + T cells possessed almost to the same extent the ability to suppress proliferation of anti-CD3/anti-CD28 stimulated syngeneic T cell and that they might be even more capable of preventing rejection in a murine skin transplant model as compared with CD4 +
CD25
+ cells [14] .Even though significantly lower as compared to CD4 +
+ cells, stable expression of Nrp1 on CD4 + CD25 2 cells has been identified in our laboratory as well as others' [15, 16] . Using a mouse model of experimental autoimmune encephalomyelitis, Solomon et al. [16] 
Cardiac transplantation and histopathological examination
Donor hearts (BALB/c) were heterotopically (intra-abdominally) transplanted into recipient mice (C57BL/6). The aorta and pulmonary arteries of the donor hearts were end-to-side anastomosed to the recipient's abdominal aorta and inferior vena cava, respectively. Survival of cardiac allografts was evaluated by daily palpation; cessation of beating was interpreted as rejection. Recipient mice received a subtherapeutic regimen of 1 mg/kg/ day i.p. Rapamycin (Sigma-Aldrich) in a vehicle containing 0.02% Tween 80 and 0.26% polyethylene glycol (both from SigmaAldrich) for 10 consecutive days (days 0-9), and/or two dose of freshly isolated CD4 + CD25 2 Nrp1
+ T cell on day 0 and day 7. The study endpoint was defined as complete cessation of cardiac beat. Survival of cardiac grafts was monitored by palpitation by two independent observers without prior knowledge of the treatment protocol, which was always confirmed with histology. Cardiac grafts were harvested whenever necessary, fixed in 10% formalin and embedded in paraffin. Sections were cut at 4 mm, and were counterstained for 1 min with hematoxylin and eosin.
Quantitative real-time PCR (qRT-PCR)
Total tissue RNA was extracted using TRIzol (Invitrogen) reagent according to the manufacturer's instructions. cDNA was synthesized using oligo d(T) (Applied Biosystems) and a SuperScript III Reverse Transcriptase Kit (Invitrogen). A StepOne 
Statistical analysis
Data from multiple groups were analyzed using one way ANOVA with post-hoc Bonferroni's correction (GraphPad Prism 5.0; GraphPad Software). Data derived from two groups were analyzed using an unpaired Student's t test or a Mann-Whitney test (two tailed). Survival rate was analyzed by the Kaplan-Meier method, and comparisons were made by log-rank analysis. All data were expressed as mean 6 SD. In all cases, p,0.05 was considered with statistical significance. To confirm the above results, allografts from each study group were harvested on day 7 post-transplantation and subjected to histological analysis. While grafts from syngeneic transplantation had intact myocardial structure, the most severe inflammatory cell infiltration and destruction of myocardial tissue structure was present in untreated allografts (Fig. 2B) . Importantly, although administration of CD4 + CD25 2 Nrp1 + T cells significantly suppressed inflammatory infiltration, we still observed impaired myocardial structure in the allografts. On the contrary, administration of CD4 +
CD25
2 Nrp1 + T cells along with Rapamycin further reduced the damage to myocardial structure without perceptible changes in inflammatory infiltration (Fig. 2C, 2D ). All these data support that CD4 + CD25 2 Nrp1 + T cells synergized with a non-therapeutic dose of Rapamycin to prolong the survival of fully MHC-mismatched cardiac allograft.
Adoptive transfer of CD4
+
CD25
2 Nrp1 + T cells changes the intragraft and systemic inflammatory cytokine expression Next, we examined the impact of CD4 +
2 Nrp1 + T cells on the expression of intragraft and serum inflammatory cytokines. To this end, on day 7 after transplantation, cardiac allografts were harvested for qRT-PCR analysis and blood was harvested for ELISA assay. Compared with allografts derived from untreated recipient mice, allografts from both Rapamycin and CD4 + CD25 2 Nrp1 + T cells treated recipients showed significantly lower levels of IFN-c and IL-17 expression, and combined therapy of Rapamycin and CD4
+ CD25 2 Nrp1 + T cells further reduced the intragraft expression of IFN-c and IL-17 (Fig. 3A, 3B ). In contrast, administration of Rapamycin together with CD4 + CD25 2 Nrp1 + T cells significantly increased the intragraft expression of IL-10, while no discernable difference for expressions were detected in Rapamycin or CD4 + CD25 2 Nrp1 + T cells alone treated mice in comparison with untreated control (Fig. 3C) . Meanwhile, administration of CD4 + CD25 2 Nrp1 + T cells rather than Rapamycin significantly increased the intragraft expression of TGF-b, and combined therapy of Rapamycin and CD4 + CD25 2 Nrp1 + T cells further increased TGF-b expression (Fig. 3D) . We also detected increased expression of Foxp3 and Nrp1 mRNA in the CD4 + CD25 2 Nrp1 + T cells but not Rapamycin-only treated recipients. Foxp3 and Nrp1 mRNA levels further increased in the mice treated with the combination of both therapies as compared with the untreated controls. Even though the Rapamycin-only treated mice showed lower Nrp1 mRNA expression within the grafted tissues, almost similar levels of Foxp3 expression in comparison with the CD4 + CD25 2 Nrp1 + T cells-only treated mice was observed (Fig. 3E, 3F) . On the protein level, we also detected significantly decreased expression of IFN-c and increased expression of IL-10 in the serum of mice treated by Rapamycin, CD4
+ CD25 2 Nrp1 + T cells alone or together treated mice as compared with that in untreated recipient mice (Fig. 3G, 3I ). In addition, CD4
+ CD25 2 Nrp1 + T cells rather than Rapamycin decreased the expression of IL-17 and increased the expression of TGF-b in the serum (Fig. 3H, 3J ). Together, we confirmed that CD4 + CD25 2 Nrp1 + T treatment changed the intragraft and systemic expression of inflammatory cytokines towards an antiinflammatory status.
CD4
+ CD25 
CD25
2 Nrp1 + T cells but not Rapamycin-only treated mice as compared with untreated controls (P,0.05, Fig. 4A, 4B) . Interestingly, the percentage of CD4
+
Foxp3
+ Treg cells was further increased in mice that received combined therapy of CD4 + CD25 2 Nrp1 + T cells and Rapamycin, and persistented in long-term allograft survivors that were sacrificed at day 42 and day 70 (Fig. 4A, 4B 
CD25
+ T cells were purified from spleens of mice sacrificed on day 21. By this method 76-83% of these CD4 + CD25 + T cells were determined to be Foxp3 + , which were then used in a suppression assay to determine their function. As shown in Fig. 4C , better suppressive capability in a dosedependent matter was found in CD4 +
+ Treg cells purified from recipient mice treated by Rapamycin combined with CD4 + CD25 2 Nrp1 + T cells as compared with those from untreated recipient mice.
CD4
+ CD25 2 Nrp1
+ T cells induce hyporesponsiveness of the T effector cells
To further dissect the mechanisms underlying the protection of CD4 + CD25 2 Nrp1 + T cells against allograft rejection, we further examined its impact on T effector cells. We isolated CD4 + CD25
2
T cells from the spleens of recipient mice treated with Rapamycin combined with CD4 + CD25 2 Nrp1 + T cells on day 70 after transplantation, and examined their proliferation upon the priming by irradiated BALB/c (donor) splenocytes. Syngeneic cardiac transplant recipients that were sacrificed at the same time post transplantation served as controls. As demonstrated in Fig. 5A , Rapamycin combined with CD4 +
CD25
2 Nrp1 + T cell treated mice showed a significant reduction (2-fold on average) in T cell proliferation. Interestingly, addition of exogenous IL-2 to the assay with CD4 +
2 T cell responders caused an almost complete restoration of responsiveness, with no significant difference between the groups. This suggests that Rapamycin combined with CD4
+ CD25 2 Nrp1 + T cells created conditions that favored induction of an anergic state in alloreactive T cells, which might contribute to the long-term allograft survival. The cytokine content of the MLRsup demonstrated significantly suppressed expression of IFN-c and IL-17 in Rapamycin combined with CD4 + CD25 2 Nrp1 + T cell treated mice, as well as increased production of IL-10 and TGF-b in comparison with the syngeneic control (Fig. 5B) . 
Discussion
Experimental and preliminary clinical evidence has demonstrated that graft tolerance could be achieved and maintained by regulatory cell therapy, including tolerogenic DCs and regulatory T cells, which are commonly referred to as CD4 +
CD25
+ Foxp3 + T cells [17, 18, 19] . However, the heterogeneity of regulatory T cells has been widely accepted [20] . Even though much attention has been paid to CD4
cells, other non-Treg immunosuppressive T cells such as CD8
+ , NKT, and cd-TCR cells have described to be required in vivo to achieve tolerance [8, 9, 21] . Additionally, TCRab + CD3 + CD4 2 CD8 2 NK1.1 2 (double negative, DN) T cells have been found to prevent graft rejection in a murine cardiac transplant model [10, 22] . Obviously, lack of insight into the phenotypes and function of non-Treg regulatory cells in vivo is halting the implementation of their therapeutic use in clinical transplantation. The reason to perform this study was therefore to assess the suppressive function of CD4 + CD25 2 Nrp1 + T cells in the setting of transplantation. We found that CD4 +
CD25
2 Nrp1 + T cells suppress anti-donor T cell responses in vitro. In combination with short-term immunosuppression (non-therapeutic dose of Rapamycin), CD4 + CD25 2 Nrp1 + T cells significantly prolonged the survival of heart grafts in a fully MHC-mismatched model.
Nrp1 was initially described as semaphorin-3A and VEGF receptor, being essential for axonal guidance and vascularization, respectively [11, 12] . In the immune system, Nrp1 has been shown to be involved in the priming of T cells by DC [23] and in the regulation of the immunological synapse and response [24, 25] . According to the study from Bruder and colleagues [13] , Nrp1 represents a surface marker for the identification of Treg cells. Because it is highly expressed on CD4 + CD25 + cells, and significantly down-regulated in activated CD4 + Tregs do not specifically express Nrp1 and Nrp1 expression is induced on peripheral blood T lymphocytes upon in vitro activation as well [26] . Inconsistently, another study has found a population of Nrp1 + Treg in human lymph nodes with Foxp3 expression that exerted contact-dependent suppression of T cell proliferation [27] . Recently, Nrp1 has been reported to be expressed at high levels by most natural Tregs, but at low levels by mucosa-generated and other noninflammatory inducible Tregs, which therefore makes Nrp1 a good surface marker to distinguish natural and inducible Tregs in vivo [28, 29] . While these contradictory results remain to be explained by further investigation, Battaglia's finding that Nrp1 was also expressed on some CD4
+ CD25 int and CD4 + CD25 2 T cells correlates well with our previous findings in mouse [15, 27] . It has been reported that Nrp1 expressed on Tregs prolongs the interaction between Tregs and immature DCs, allowing Tregs more time to recognize MHC class II-peptide complexes presented by iDCs, which results in higher sensitivity when limiting amounts of antigen are present [30] . Moreover, Nrp1 is a receptor for TGF-b1 and activates its latent form, which is also relevant to the Tregs' activity [31] . These findings suggest that besides being a surface marker, Nrp1 could be a key player in the list of molecules by which regulatory cells exert their suppressive effects. This raises the question whether Nrp1-expressing non- 
2 Nrp1 + T cells were reported to exert their suppressive function through TGF-b-dependent but not IL-10-dependent pathways during autoimmune inflammatory responses. Although we did not address this in our study, we did observe significantly elevated expression of both TGF-b and IL-10 in the CD4 + CD25 2 Nrp1 + T cells treated mixed lymphocyte reaction supernatants, recipient mice sera and allograft homogenates.
Our results showed a decrease in IFN-c and IL-17 cytokines in recipients that have received CD4
+ CD25 2 Nrp1 + T cells, indicating suppressed Th1 and Th17 response. IL-17 was reported to be a product of neutrophils during the early postoperative period and subsequently by Th17 and CD8 + T cells during allograft rejection in mice [32] . Consistently, we found that administration of CD4 + CD25 2 Nrp1 + T cells significantly suppressed inflammatory infiltration in the allograft. Meanwhile, we also observed increased frequency of CD4 + Foxp3 + T cells in the long-term surviving CD4 + CD25 2 Nrp1 + T cells treated mice, suggesting an imbalance of Th17/Tregs towards the accumulation of Tregs. The increased expression of TGF-b might be one promoter for the development of CD4
+
Foxp3
+ T cells [33] . However, the exact sequence of events that is induced by CD4 + CD25 2 Nrp1 + T cells treatment during transplant immune response as well as their exact correlations remains to be investigated. Analysis of T cell reactivity in long-term surviving grafts from recipients indicated that, at 70 days post-transplant, the combination of Rapamycin and CD4 + CD25 2 Nrp1 + T cells promotes conversion of alloreactive T cells to an anergic state, which seems to be another possible mechanism for the protection induced by CD4 +
CD25
2 Nrp1 + T cells against allograft rejection.
Rapamycin has been shown to be able to exert synergistic effects together with Tregs in preventing in vivo allorejection, including freshly isolated, in vitro or in vivo expanded, and antigen specific Tregs, while Tacrolimus and Cyclosporine A displayed opposite effects when combine used with Treg [7, 34, 35] . We found in this study that Rapamycin alone can suppress the pro-inflammatory and potentiates the anti-inflammatory cytokine expression both in the recipients sera and in the allograft homogenates. However, Rapamycin alone failed to increase the CD4 + Foxp3 + T cells frequency in the recipient's spleen. To date, two studies have described the interaction between Nrp1 and the mTOR pathway. Bae and colleagues describe that autophagy, which was induced by administration of Rapamycin, associated with a reduction in the expression of Nrp1 on the surface of endothelial and carcinoma cells, which is somewhat counter-intuitive with a direct intracellular synergistic effect [36] . Whether Rapamycin via autophagy induces the breakdown of Nrp-1 in CD4 + CD25 2 T cells as well is not known. Manns et al. describe that dose-dependent Nrp1-receptor complex stimulation with semaphoring-3A in axons, via the stabilization of GSK3-b also had upstream effects on the mTOR pathway, which resulted in altered protein synthesis and degradation [37] . Rapamycin, independent from semaphoring-3A stimulation, further potentiated these processes in vitro. According to the report of Raimondi et al., the innate immune response after organ transplantation may convert T effector cells to a state refractory to Treg suppression, and inflammatory cytokines such as IL-6 might play a critical role in this process. Rapamycin treatment can alleviate the inflammatory response after organ transplantation, and hence increase the suppressive function of Tregs. Consistently, we also found longer survival in the combined therapy group as compared with either Rapamycin or CD4 + CD25 
2 Nrp1 + T Cells Prevent Cardiac Rejection
